Posts tagged ‘bladder cancer’


Bladder cancer: What you need to know (w/INFOGRAPHIC)

August 7, 2015 | by

Bladder Cancer Infographic

 

» Continue Reading


Bladder cancer treatment is evolving. Here are 3 important advances

July 16, 2015 | by

In years past, Bladder Cancer Awareness Month has been a sobering reminder of a disease with few treatment options. For patients with metastatic disease (disease that has spread from the bladder to distant organs), average survival is typically just over one year. Fortunately, things are changing.

stages of bladder cancer

Bladder cancer treatment is advancing. Here are three of the most promising approaches. (Illustrated here, bladder cancer in stages.)

Academic institutions like City of Hope now have a wealth of clinical trials for patients with bladder cancer. These clinical trials are examining drugs that work through a number of mechanisms distinct from chemotherapy. Highlighted below are the top three research and treatment advances that I feel are the most promising:

1. Redirecting the immune system

We have several ongoing studies looking at a class of drugs called programmed death-1, or PD-1, inhibitors. In a patient with cancer, the immune system is often suppressed, making it challenging for the body to mount any response against cancer cells. PD-1 inhibitors (and a closely related class of drugs called PD-L1 inhibitors) cause dormant immune cells to reactivate, therefore overcoming this suppression.

Not every patient will respond to PD-1 or PD-L1 inhibitors, but those who do often have extremely prolonged responses, with existing studies documenting survival of up to several years.

» Continue Reading


New trends and developments in bladder cancer (w/PODCAST)

July 13, 2015 | by
bladder cancer

Bertram Yuh is a urological cancers expert at City of Hope, an institution known for its cancer treatment and research.

Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder.

Among both men and women, the rates of new cancers have decreased in recent years. Death rates, meanwhile, have declined among women and have held stable among men.

Specialists at City of Hope are internationally recognized experts in the treatment of bladder cancer. As one of a few institutions to attain the elite designation of comprehensive cancer center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and treatment.

City of Hope also offers numerous bladder cancer clinical trials and is constantly working to develop and deliver the latest treatment strategies for any stage of bladder cancer.

In this podcast, Bertram Yuh, M.D., discusses bladder cancer, how a person can lower his or her risk and what types of developments have been made in bladder cancer treatment in the past few years.

 

**

For other interviews with City of Hope experts,  go to our list of City of Hope podcasts.

**

Learn more about becoming a patient or getting a second opinion at City of Hope by visiting our website or by calling 800-826-HOPE (4673). You may also request a new patient appointment online. City of Hope staff will explain what’s required for a consult at City of Hope and help you determine, before you come in, whether or not your insurance will pay for the appointment.


Our bladder cancer experts give patients more, and better, choices

July 1, 2015 | by

“With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.”

bladder cancer alternative

Bladder alternative allows bladder cancer patients to live a more normal life.

To meet this challenge, Chan and the urologic team at City of Hope ensure that bladder cancer patients who need a cystectomy, or bladder removal, are fully aware of their options. According to Chan, the majority of urologic surgeons will recommend only an “incontinent diversion,” in which the urine drains into an external bag.

But at City of Hope, 60 percent of patients receive “continent diversions” — either a neobladder or Indiana pouch—in which a section of intestine is used to create an internal reservoir. The neobladder allows patients to urinate out of their urethra, whereas the Indiana pouch results in a stoma on the abdomen that patients catheterize to empty.

“We spend an hour with each patient, explaining all three reconstructive procedures,” said Chan. “We go through the pros and cons of each one in that patient’s particular situation. And as long as it’s reasonable and makes sense from a cancer perspective, we will do everything we can to give them the reconstruction they want.” » Continue Reading


Cancer Insights: What I’ll be looking for in Chicago – an ASCO 2015 preview

May 27, 2015 | by

The American Society of Clinical Oncology (ASCO) is a U.S.-based organization that ties together oncology health care professionals (doctors, nurses and pharmacists) from around the world. The organization’s annual meeting represents a key forum in which scientific breakthroughs in oncology are unveiled. Attendance is nothing short of spectacular – last year, the meeting drew 34,000 attendees with just over half coming from outside of the U.S.

ASCO 2015: What's hot

ASCO 2015 preview: For a medical oncologist specializing in prostate, kidney and bladder cancer, the annual meeting of the nation’s top oncologists is a learning opportunity that can’t be missed. One of the most promising topics is about a clinical trial using gene therapy.

This year’s meeting begins Thursday in Chicago. After a busy clinic today, I’m going to hop on a red-eye and make my way there. As a medical oncologist focused on prostate, kidney and bladder cancer, I’ll be focused on the following research in particular:

1. “Gene therapy” for bladder cancer: The BOREALIS-1 trial: For years we have longed for new therapies for advanced bladder cancer. It’s been three decades since cisplatin (a standard chemotherapy agent) was introduced for the disease, and since that time, we’ve had virtually no effective drugs developed. This appears to be changing dramatically.

My friend and colleague Przemyslaw Twardowski, M.D., was involved in an international study evaluating a novel drug called apatorsen. Apatorsen represents a sort of “gene therapy” – a short strand of DNA that enters the cancer cell and shuts down its defense mechanisms. At this meeting, we will see data suggesting that when added to chemotherapy, apatorsen led to an impressive improvement in survival.

That data is a real glimmer of hope for patients with advanced bladder cancer. » Continue Reading


Bladder cancer patient has a mission: Cure metastatic bladder cancer

March 27, 2015 | by
Frank Di Bella, pictured with Sumanta Kumar Pal, M.D., raised more than $1.6 million for metastatic bladder cancer research led by Pal at City of Hope.

Frank Di Bella (right), pictured with Sumanta Kumar Pal, has already helped raise more than $1.6 million for metastatic bladder cancer research led by Pal at City of Hope.

Frank Di Bella, 70, is on a mission: Find a cure for metastatic bladder cancer.

It’s just possible he might.

Although Di Bella isn’t a world-renowned physician, cancer researcher or scientist, he knows how to make things happen. For more than 20 years, he served as chairman of annual fundraising galas on behalf of muscular dystrophy research, and he’s successfully raised more than $10 million toward that cause.

Now his attention is focused on his own disease: metastatic bladder cancer. The certified public accountant recently held a black-tie gala titled “Let’s Be Frank about Cancer” to help raise funds for City of Hope’s bladder cancer research, led by Sumanta Kumar Pal, M.D.

The gala was filled with distinguished leaders, such as Gov. Jerry Brown, and brought in more than $1.6 million for Pal’s research.

But for Di Bella, that’s just the start.

“I’m going to spend the rest of my life raising money to help City of Hope and Dr. Pal,” Di Bella said.

» Continue Reading


Cancer Insights: The dawn of precision medicine for cancer

March 17, 2015 | by

“Tonight, I’m launching a new precision medicine initiative to bring us closer to curing diseases like cancer.” These were the words of President Barack Obama on Jan. 20, 2015, during his State of the Union address. So what is precision medicine, and how close are we to making it a reality for patients?

Potential of precision medicine

Precision medicine is rapidly becoming a reality. With it comes an unprecedented potential to treat patients as the individuals they are.

Let’s begin with some definitions. Precision medicine entails two general tenets: (1) understanding the biology of an individual patient’s cancer, and (2) treating the patient according to this biology. When I was in medical school, both elements would have been perceived as a pipe dream. Now, they are slowly becoming a reality.

Comprehensive genetic tests that used to take days to weeks to run can now be done in minutes; these tests can point an oncologist toward specific medications that target proteins at the cancer cell surface, while sparing normal cells. In contrast to chemotherapy (which attacks cells indiscriminately), targeted therapies may potentially have fewer side effects. » Continue Reading


Meet our doctors: Surgeon Donald Hannoun on urology and bladder cancer

February 7, 2015 | by

The treatment of urologic cancers, including bladder cancer, is rapidly evolving. Here, urologic oncologic surgeon and kidney stone specialist Donald Hannoun, M.D., an assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope | Antelope Valley, explains the changes in his field, as well as his approach to medicine.

Urologist Donald Hannoun

Donald Hannoun shares his approach to urology and patient care.

Did someone or something from your early experience in life motivate you to go into medicine?

I’ve always loved working with people.  I couldn’t think of a more altruistic field than medicine. What motivated me to get into urology was my late grandfather’s struggle with bladder stones, which are hard masses of minerals in the bladder. He was completely miserable before his surgery, and was then transformed into a new man after having them removed. To see such immediate results made me seriously consider urology. Now, I treat all types of genitourinary cancers, including kidney, bladder, prostate and testicular cancer.

» Continue Reading


Cancer research 2015: T cell immunotherapy, targeted drugs and more

January 1, 2015 | by

Every year, researchers make gains in the understanding of cancer, and physicians make gains in the treatment of cancer. As a result, every year, more cancer patients survive their disease.

2015 in cancer research

In 2015, cancer research will move forward in ways both high-profile and little-heralded.

In those ways, 2015 will be no different. What will be different are the specific research discoveries and the specific advances in screening and treatment. We asked City of Hope experts to weigh in on the research and treatment advances they predict for the year to come.

Some of those advances will make headlines around the world – expect to hear much more about T cell therapy and targeted drug therapy – while some will garner attention largely among those affected by, or treating, the disease.

But all will have an impact. » Continue Reading


Bladder cancer 2015: Personalized medicine meets ‘molecular selection’

December 28, 2014 | by

Surgery for bladder cancer isn’t what it used to be; it’s better – much better. Advances in robotic surgeries have greatly improved both the options and the quality of life for people diagnosed with bladder cancer.

bladder cancer

City of Hope is leading several innovative studies in bladder cancer, with two of them focusing on what’s known as a molecular selection process.

These advances, which are constantly giving way to even newer ones, mean that the entire bladder doesn’t always have to be removed. When it does, not only can highly skilled surgeons sometimes create an artificial bladder, they can even create an internal reservoir (different from a bladder and known as an Indiana pouch) using the large intestine and part of the small intestine. Such alternatives are usually preferred  over the need for an external bag to collect the urine.

Much work remains, however, in the understanding of bladder cancer. Sumanta Pal, M.D., co-director of the Kidney Cancer Program at City of Hope, is leading several innovative studies in bladder cancer, with two of them focusing on what’s known as a molecular selection process. » Continue Reading